Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The laboratory is equipped to perform high-volume diagnostic testing services
Results reinforce commitment to next-generation oral SERD development programme
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Study achieves primary endpoint of radiographic progression-free survival
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
There is also a growing interest in whole generation sequencing (WGS)
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Subscribe To Our Newsletter & Stay Updated
